For about twenty years, the most commonly used drug for wet age-related macular degeneration has reached retina clinics by an unusual route. A pharmacy buys a vial of bevacizumab labeled and manufactured as an intravenous cancer infusion, draws it into syringes under sterile conditions, and ships those syringes to ophthalmologists, who inject a fraction of a milliliter into a patient's eye. That practice is legal, widespread, supported by clinical evidence, and has never involved a product the FDA approved for use in the eye.
That changed last week. The FDA approved Lytenava (bevacizumab-vikg) from Outlook Therapeutics for neovascular AMD, the first ophthalmic formulation of bevacizumab the agency has ever cleared in the United States.
For patients, the immediate practical change is small. The molecule is the same one many have been receiving for years, and there is no reason for anyone to stop or switch treatment. What changes is the accountability structure behind the syringe.
Why Repackaging Became the Standard and Where It Strains
Bevacizumab works in the eye because wet AMD is driven by vascular endothelial growth factor, the same protein the drug was designed to block in tumors. Abnormal vessels grow beneath the macula, leak fluid and blood, and destroy central vision quickly. Anti-VEGF injections interrupt that process.
Economics made bevacizumab the default. A repackaged dose has typically cost a small fraction of branded anti-VEGF agents, and large publicly funded comparative trials found it performed comparably to a far more expensive alternative for most patients. That combination made it the workhorse of retina care and a meaningful restraint on Medicare spending.
The strain is in the supply chain rather than the science. Compounding pharmacies operate under a different regulatory framework than drug manufacturers. Each repackaging step introduces a point where sterility, protein aggregation, silicone oil from syringes, endotoxin levels or dose volume can vary between batches or between vendors. Clusters of severe intraocular inflammation and infection traced to specific compounded lots have been reported periodically over the years, and each incident required investigators to work backward through a chain the FDA does not inspect the way it inspects a licensed biologic plant.
An approved ophthalmic product moves that chain inside the regulatory perimeter. Outlook describes the approval as supported by "validated manufacturing, approved labeling, comprehensive quality systems" and ongoing FDA oversight. That is the company's framing, but the underlying distinction is real. Adverse events, lot recalls, and manufacturing deviations now flow through the same reporting machinery that governs every other approved biologic.
Outlook chief executive Bob Jahr noted the anomaly the approval resolves, saying bevacizumab has served as "one of the most widely utilized anti-VEGF therapies in retina care" despite the absence of an approved ophthalmic version.
What Wet AMD Is and Who Gets It
Age-related macular degeneration damages the macula, the small central region of the retina responsible for reading, driving, and recognizing faces. It does not cause total blindness, because peripheral vision is preserved, but it takes the vision people depend on most.
Roughly 20 million Americans have some form of AMD. The wet, or neovascular, form is the minority variant and the dangerous one. According to the BrightFocus Foundation, wet AMD accounts for about 10 percent of AMD cases yet is "responsible for 90% of legal blindness" from the disease.
Wet AMD is always preceded by the dry form, and it can move fast. Untreated, many affected eyes lose central vision within a year. That speed is why the warning signs matter. Straight lines that appear wavy or bent, a new blurred or dark spot in the center of vision, or a sudden change in reading vision are reasons to contact an eye care professional promptly rather than waiting for a routine appointment. Risk climbs after age 60 and with smoking, family history, and cardiovascular disease.
The Regulatory Road Was Not Smooth
This approval should not be read as a straightforward endorsement. The FDA issued a Complete Response Letter in December 2025, telling the company that the mechanistic and natural history data submitted were insufficient and that additional confirmatory efficacy data were needed. Outlook resubmitted on June 1; the agency accepted the application on June 16, and approval came on July 24, ahead of a target action date of July 29.
The application rests on the NORSE clinical trial program. Independent retina specialists have debated for years whether an approved bevacizumab adds enough over the compounded version to justify a premium, and the approval does not settle that debate. Nothing in it declares compounded bevacizumab unsafe, and the compounded product remains available.
The company also projects 12 years of reference product exclusivity under the biosimilars statute, which is a claim about market protection rather than a clinical finding.
The Question the Approval Does Not Answer
Price. Outlook has not announced what Lytenava will cost. The company says it is preparing a U.S. commercial launch with reimbursement and patient support programs and expects availability before the end of 2026.
This is what will determine whether the approval helps patients or mainly reshuffles spending. Compounded bevacizumab has been inexpensive precisely because it sits outside the branded pricing system. An approved version priced near other branded anti-VEGF agents would raise costs for Medicare and for patients paying coinsurance, without changing the molecule going into the eye. Priced modestly above compounded product, it could displace repackaging while preserving the cost advantage that made bevacizumab standard.
Medicare beneficiaries typically owe 20 percent coinsurance on physician-administered drugs unless they carry supplemental coverage, so list price translates directly into household cost for people receiving injections every four to eight weeks, often indefinitely.
What Patients Should Do Now
Nobody needs to act today. Anyone currently receiving anti-VEGF injections should keep their schedule, because missed injections carry a documented risk of vision loss that far outweighs any concern raised here.
At the next appointment, it is reasonable to ask which bevacizumab product the practice uses, whether it intends to switch, and what the out-of-pocket cost would be under either option. Patients on fixed incomes should ask about coinsurance before a switch happens rather than after the first bill arrives.
People with dry AMD or a family history should keep to their monitoring schedule and use an Amsler grid at home if their ophthalmologist has recommended one, since catching conversion to the wet form early is what preserves vision.
What Happens Next
Three things are worth watching. Pricing and reimbursement details, which the company has not released. Whether large retina practices and hospital systems adopt the approved product or stay with compounded preparations. And whether the FDA or state pharmacy boards revisit oversight of ophthalmic compounding now that a licensed alternative exists.
The newest confirmed fact is that an ophthalmic bevacizumab is approved for the first time. The people most affected are the roughly 200,000 North Americans diagnosed with wet AMD each year and the far larger group already receiving injections. The most reasonable step is a question at the next appointment. The central uncertainty is cost.
Frequently Asked Questions
What was approved? The FDA approved Lytenava (bevacizumab-vikg), the first ophthalmic formulation of bevacizumab for wet age-related macular degeneration in the United States.
How is this different from what patients get now? Most patients receive bevacizumab repackaged by compounding pharmacies from an intravenous cancer product. The approved version is manufactured, labeled, and inspected specifically for injection into the eye.
Is compounded bevacizumab unsafe? The approval does not say so, and it remains in use. Compounding adds steps where sterility and dosing can vary, which is what an approved formulation is designed to standardize.
What is wet AMD? The neovascular form of macular degeneration, in which abnormal blood vessels grow under the macula and leak. It is about 10 percent of AMD cases and most of the severe vision loss.
What symptoms should prompt a call? Straight lines appearing wavy, a new blurred or dark spot in central vision, or a sudden change in reading vision.
What will it cost? Not announced. Pricing is the open question, since compounded bevacizumab has been far cheaper than branded anti-VEGF drugs.
Should I change treatment? No. Do not stop or delay scheduled injections. Ask your retina specialist which product they use and what your share of the cost would be.
